Products
- Anti-Obesity Compound Library
- GPCR/G Protein-Targeted Compounds
- Immunology/Inflammation-Targeted Compounds
- JAK/STAT-Targeted Compounds
- MAPK-Targeted Compounds
- Membrane Transporter/Ion Channel-Targeted Compounds
- Metabolism-Targeted Compounds
- NF-κB-Targeted Compounds
- Microbiology/Virology-Targeted Compounds
- Neuronal Signaling-Targeted Compounds
- PI3K/Akt/mTOR-Targeted Compounds
- Oxidation-reduction-Targeted Compounds
- Proteases/Proteasome-Targeted Compounds
- Stem Cells/Wnt-Targeted Compounds
- Tyrosine Kinase/Adaptors-Targeted Compounds
- Ubiquitin-Targeted Compounds
Online Inquiry
Mito-LND
Cat. No.:
OB0225LY-0445
Appearance:
Viscous
Purity:
≥98%
Identity:
Confirmed by NMR, HPLC, and LC-MS.
Size:
Add to basket
Product Overview
Description:
Mito-LND is a multi-targeted small molecule drug specifically designed to target mitochondria to enhance cellular antioxidant capacity and regulate cellular metabolism.
Synonym:
Mito-Loidamine; 2361564-49-8; 10-[[1-[(2,4-Dichlorophenyl)methyl]indazole-3-carbonyl]amino]decyl-triphenylphosphanium bromide; [10-({1-[(2,4-Dichlorophenyl)methyl]indazol-3-yl}formamido)decyl]triphenylphosphanium bromide
CAS No.:
2361564-49-8
Compound CID:
155977659
Formula:
C43H45BrCl2N3OP
Formula Weight:
801.62
Specification
Stability:
3 years in powder form.
Storage:
Storage at -20°C.
Applications:
Mito-LND can be used in cell biology studies to explore mitochondrial function and its important role in cellular metabolism, or in the study of oxidative stress-related diseases.
Library Information
Targets:
Mitochondrial metabolism
Receptors:
Oxidative phosphorylation (OXPHOS)
Pathways:
Apoptosis; Metabolism; Immunology/Inflammation; NF-κB; Autophagy
Plate Number:
AOCL-6
Plate Location:
g2
Empty Location:
a1-h1; a12-h12
Container:
96-well plate
Formulation:
10 mM DMSO
DMSO Max Solubility:
45 mg/mL; 56.14 mM
